MedKoo Cat#: 555454 | Name: FKGK18
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FKGK18 is the most potent inhibitor of GVIA iPLA(2) (X(I)(50) = 0.0002) ever reported. Being 195 and >455 times more potent for GVIA iPLA(2) than for GIVA cPLA(2) and GV sPLA(2), respectively. Group VIA calcium-independent phospholipase A(2) (GVIA iPLA(2)) has recently emerged as a novel pharmaceutical target.

Chemical Structure

FKGK18
CAS#1071001-09-6

Theoretical Analysis

MedKoo Cat#: 555454

Name: FKGK18

CAS#: 1071001-09-6

Chemical Formula: C16H15F3O

Exact Mass: 280.1075

Molecular Weight: 280.29

Elemental Analysis: C, 68.56; H, 5.39; F, 20.33; O, 5.71

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 550.00 2 Weeks
25mg USD 1,050.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
FKGK18; FKGK-18; FKGK 18;
IUPAC/Chemical Name
1,1,1-Trifluoro-6-(2-naphthalenyl)-2-hexanone
InChi Key
VCWWTQMRNJSJGC-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H15F3O/c17-16(18,19)15(20)8-4-1-5-12-9-10-13-6-2-3-7-14(13)11-12/h2-3,6-7,9-11H,1,4-5,8H2
SMILES Code
O=C(CCCCC1=CC=C2C=CC=CC2=C1)C(F)(F)F
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 280.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bone RN, Gai Y, Magrioti V, Kokotou MG, Ali T, Lei X, Tse HM, Kokotos G, Ramanadham S. Inhibition of Ca2+-independent phospholipase A2β (iPLA2β) ameliorates islet infiltration and incidence of diabetes in NOD mice. Diabetes. 2015 Feb;64(2):541-54. doi: 10.2337/db14-0097. Epub 2014 Sep 11. PubMed PMID: 25213337; PubMed Central PMCID: PMC4303959. 2: Ali T, Kokotos G, Magrioti V, Bone RN, Mobley JA, Hancock W, Ramanadham S. Characterization of FKGK18 as inhibitor of group VIA Ca2+-independent phospholipase A2 (iPLA2β): candidate drug for preventing beta-cell apoptosis and diabetes. PLoS One. 2013 Aug 20;8(8):e71748. doi: 10.1371/journal.pone.0071748. eCollection 2013. PubMed PMID: 23977134; PubMed Central PMCID: PMC3748103. 3: Kokotos G, Hsu YH, Burke JE, Baskakis C, Kokotos CG, Magrioti V, Dennis EA. Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10. doi: 10.1021/jm901872v. PubMed PMID: 20369880; PubMed Central PMCID: PMC2865582.